|
|
|
Lymphoma Research at the UC Davis Cancer Center
|
Dedicated to Improving Treatments for Lymphoma
|
|
 |
 |
| |
|
Joseph M. Tuscano, M.D.
Associate Professor
U.C. Davis Cancer Center
Specialty: Hematology and Oncology
|
Residence: Folsom, California, USA
Birthplace: Yuba City, California, USA
Undergraduate Education:
California State University Sacramento, California B.S.1984
Medical Education:
University of Southern California School of Medicine
Los Angeles, California M.D. 1989
Internship:
University of California, Davis Medical Center
Sacramento, California 1989-92
Internal Medicine
Residency:
University of California, Davis Medical Center
Sacramento, California 1989-92
Internal Medicine
Fellowship:
National Institutes of Health
Bethesda, Maryland 1992-94
Immunology
National Institutes of Health
Bethesda, Maryland 1994-96
Oncology
Board Certifications:
American Board of Internal Medicine,
American Board of Internal Medicine, Hematology & Oncology,
Professional Memberships:
American Association for the Advancement of Science
American College of Physicians
American Medical Association
Clinical/Research Interests:
Dr. Tuscano’s areas of specialty include bone marrow transplantation with high-dose chemotherapy (either alone or in conjunction with radioimmunotherapy) for metastatic breast cancer, lymphoma, leukemia, testicular cancer, and multiple myeloma. He researches signal transduction, notably in human B cell malignancies. Dr. Tuscano has identified a signal cascade implicated in chronic myelogenous leukemia and is looking at other proteins thought to affect lymphoma.
Publications:
Shi CS, Tuscano J, Kehrl JH. Adaptor proteins CRK and CRKL Associate with the Serine/Threonine Protein Kinase GCKR Promoting GCKR and SAPK Activation. Blood;95(3):776-782. 2000
Tuscano JM, Riva A, Toscano SN, Tedder TF, and Kehrl JH. CD22 Cross-linking Generates B Cell Antigen Receptor-independent Signals that Activate the JNK/SAPK Signaling Cascade. Blood; 94(4): 1-12. 1999
Shi CS, Tuscano JM, Witte ON, Kehrl JH. GCKR Links the Bcr-Abl Oncogene and Ras to the Stress Activated Protein Kinase Pathway. Blood; 93(4): 1338-1345. 1999
Sato S, Tuscano JM, Inaioki M, Tedder TF. CD22 Negatively and Positively Regulates Signal Transduction Through the B Lymphocyte Antigen Receptor. Seminars in Immunology 10:287-297. 1998
Tedder TF, Tuscano J, Sato S, Kehrl JH.CD22, a B Lymphocyte-Specific Adhesion Molecule That Regulates Antigen Receptor Signaling. Annual Review of Immunology. 15:481-504. 1997
Riekmann P, Tuscano JM, Kehrl JH. Tumor Necrosis Factor- (TNF- ) and Interleukin-6(IL-6) in B Lymphocyte Function. Methods; 11:128/32. 1997
Tuscano JM, Druey KM, Riva A, Pena J, Thompson CB,and Kehrl JH. Bcl-x Rather than Bcl-2 Mediates CD40-Dependent Centrocyte Survival in the Germinal Center. Blood, 88(6) 1359-1364. 1996
Tuscano JM, Engler P, Tedder TF, Aggarwal A, Kehrl JH. Involvement of p72 Syk Kinase, p53/56 Lyn Kinase, and PI-3 Kinase In Signal Transduction via the Human B Lymphocyte Antigen CD22. European Journal of Immunology, 26(6) 1246-1253. 1996.
Tuscano JM, Engel P, Tedder TF, Kehrl JH. Engagement of CD22 Triggers a Potent stimulatory Signal for B-cells and Blocking a CD22/CD22L Interaction Impairs T-cell Proliferation. Blood,86(11)4723-4730. 1996
Tortolani JP, KL Brajesh, Riva A, Johnston JA, Chen YQ, Reaman GH, Beckwith M, Longo D, Ortaldo JR, Bhatia K, McGrath I, Kehrl JH, Tuscano JM, McVicar DW, O'Shea JJ. Regulation of JAK3 Expression and Activation in Human B Cells and B Cell Malignancies. Journal of Immunology,155:15220-15226. 1995
|
|
|
